X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6624) 6624
Newsletter (51) 51
Book / eBook (4) 4
Book Chapter (4) 4
Government Document (3) 3
Dissertation (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4664) 4664
male (3092) 3092
animals (2762) 2762
pyridines - pharmacokinetics (2533) 2533
pyridines - pharmacology (2150) 2150
female (2136) 2136
pharmacology & pharmacy (1993) 1993
pyridines - therapeutic use (1735) 1735
adult (1443) 1443
pyridines - administration & dosage (1435) 1435
middle aged (1307) 1307
rats (1287) 1287
pyridines - adverse effects (1108) 1108
pharmacokinetics (1022) 1022
mice (1019) 1019
aged (922) 922
oncology (880) 880
dose-response relationship, drug (834) 834
pyridines - chemistry (815) 815
administration, oral (804) 804
chemistry, medicinal (623) 623
cancer (613) 613
pyridines - blood (611) 611
treatment outcome (611) 611
analysis (571) 571
drug interactions (495) 495
neurosciences (492) 492
rats, sprague-dawley (482) 482
structure-activity relationship (481) 481
pyridine (457) 457
research (448) 448
pharmacology/toxicology (427) 427
pyridines - metabolism (420) 420
pyridines - chemical synthesis (417) 417
antineoplastic agents - therapeutic use (412) 412
drug therapy (412) 412
pharmacology (409) 409
medicine & public health (407) 407
care and treatment (403) 403
niacinamide - analogs & derivatives (399) 399
phenylurea compounds (375) 375
biochemistry & molecular biology (368) 368
safety (367) 367
brain - metabolism (365) 365
double-blind method (352) 352
tissue distribution (343) 343
time factors (340) 340
atazanavir sulfate (339) 339
cell line, tumor (334) 334
half-life (325) 325
biological availability (324) 324
young adult (320) 320
area under curve (316) 316
hiv infections - drug therapy (314) 314
in-vitro (301) 301
aged, 80 and over (298) 298
antineoplastic agents - pharmacology (298) 298
chemotherapy (295) 295
drug administration schedule (294) 294
health aspects (291) 291
dogs (289) 289
molecular structure (288) 288
toxicology (285) 285
dabigatran (283) 283
therapy (278) 278
sorafenib (277) 277
adolescent (276) 276
disease models, animal (276) 276
expression (273) 273
protein kinase inhibitors - therapeutic use (271) 271
efficacy (270) 270
metabolism (269) 269
clinical trials (267) 267
clinical trials as topic (262) 262
kinetics (262) 262
pyridines (260) 260
chemistry, organic (250) 250
antineoplastic agents - pharmacokinetics (248) 248
double-blind (246) 246
drug therapy, combination (246) 246
rats, wistar (243) 243
zolpidem (243) 243
dosage and administration (235) 235
neoplasms - drug therapy (234) 234
antineoplastic agents - adverse effects (232) 232
inhibitor (229) 229
brain (228) 228
pharmacodynamics (228) 228
imidazoles - pharmacology (225) 225
in vitro techniques (225) 225
internal medicine (225) 225
drugs (224) 224
psychiatry (222) 222
infectious diseases (220) 220
biomedicine (219) 219
protein kinase inhibitors - pharmacology (218) 218
oligopeptides - pharmacokinetics (213) 213
brain - diagnostic imaging (211) 211
hematology (211) 211
prevention (209) 209
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6604) 6604
Japanese (48) 48
German (47) 47
French (20) 20
Spanish (12) 12
Russian (11) 11
Chinese (6) 6
Dutch (6) 6
Danish (3) 3
Italian (3) 3
Norwegian (3) 3
Portuguese (2) 2
Czech (1) 1
Polish (1) 1
Swedish (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
... of approximately 1.8 log 10  copies ml −1 , and a pharmacokinetic/pharmacodynamic (PK/PD) relationship was identified and characterized. Furthermore, no NNRTI resistance... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2009, Volume 35, Issue 8, pp. 692 - 706
.... Post marketing study commitments have been made upon (accelerated) approval such as additional pharmacokinetic studies in patients with renal- or hepatic impairment... 
Hematology, Oncology and Palliative Medicine | Excretion | Absorption | Metabolism | Tyrosine kinase inhibitors | Distribution | Drug transporters and interactions | CHRONIC MYELOGENOUS LEUKEMIA | RENAL-CELL CARCINOMA | CHRONIC MYELOID-LEUKEMIA | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHRONIC MYELOCYTIC-LEUKEMIA | ADVANCED SOLID MALIGNANCIES | IMATINIB MESYLATE GLEEVEC | GASTROINTESTINAL STROMAL TUMORS | CEREBROSPINAL-FLUID PHARMACOKINETICS | CANCER RESISTANCE PROTEIN | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Pyrroles - pharmacokinetics | Humans | Cytochrome P-450 Enzyme System - metabolism | Pyridines - pharmacokinetics | Quinazolines - pharmacokinetics | Biological Availability | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Intestinal Absorption | Thiazoles - pharmacokinetics | Antineoplastic Agents - metabolism | Tissue Distribution | Benzenesulfonates - pharmacokinetics | Drug Interactions | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperazines - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Dasatinib | Administration, Oral | Imatinib Mesylate | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Protein Kinase Inhibitors - pharmacology | Benzamides | Protein Kinase Inhibitors - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Oncology, Experimental | Cytochrome P-450 | Physiological aspects | Phenols | Research | Phosphotransferases | Protein binding | Cancer | Index Medicus
Journal Article
AIDS (London), ISSN 0269-9370, 2007, Volume 21, Issue 14, pp. 1899 - 1907
...: Non-blinded, single center, open-label pharmacokinetic study in HIV-infected women. Method: Twenty-seven women initiating combination antiretroviral therapy... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | VALIDATION | PREVENTION | PENETRATION | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | VIROLOGY | LIQUID-CHROMATOGRAPHY | pharmacokinetics | INFECTION | MACAQUES | TENOFOVIR | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 67, Issue 24, pp. 2888 - 2899
... dialysis. The authors review the current pharmacokinetic, observational, and prospective data on NOACs in patients with advanced chronic kidney disease... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | apixaban | stroke | edoxaban | renal dialysis | CARDIAC & CARDIOVASCULAR SYSTEMS | APPENDAGE CLOSURE | PLATELET-AGGREGATION | SAFETY | PHARMACOKINETICS | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | HEMODIALYSIS-PATIENTS | NONVALVULAR ATRIAL-FIBRILLATION | STAGE RENAL-DISEASE | WARFARIN USE | Pyrazoles - therapeutic use | Dabigatran - pharmacokinetics | Humans | Pyridines - pharmacokinetics | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - pharmacokinetics | Warfarin - therapeutic use | Renal Insufficiency, Chronic - therapy | Kidney - metabolism | Pyrazoles - pharmacokinetics | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Stroke - prevention & control | Glomerular Filtration Rate | Pyridones - pharmacokinetics | Atrial Fibrillation - drug therapy | Anticoagulants - therapeutic use | Creatinine - urine | Warfarin - pharmacokinetics | Kidney Failure, Chronic - therapy | Rivaroxaban - pharmacokinetics | Kidney Failure, Chronic - complications | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Hemorrhage - chemically induced | Renal Dialysis | Stroke (Disease) | Medical colleges | Care and treatment | Continuing medical education | Warfarin | Chronic kidney failure | Atrial fibrillation | Mortality | Medical care | Quality management | Urine | Confidence intervals | Disease prevention | Anticoagulants | Stroke | Hemodialysis | Kidney diseases | Metabolism | Drug dosages
Journal Article
Journal Article
Journal Article